Deutsche Bank AG Has $1.47 Million Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Deutsche Bank AG raised its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 53.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 217,723 shares of the company's stock after acquiring an additional 75,994 shares during the period. Deutsche Bank AG owned approximately 0.06% of Recursion Pharmaceuticals worth $1,472,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Private Trust Co. NA purchased a new stake in Recursion Pharmaceuticals during the fourth quarter valued at about $27,000. Farther Finance Advisors LLC grew its stake in shares of Recursion Pharmaceuticals by 21.1% in the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after buying an additional 1,353 shares in the last quarter. NewEdge Advisors LLC grew its stake in shares of Recursion Pharmaceuticals by 43.7% in the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock valued at $53,000 after buying an additional 2,387 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Recursion Pharmaceuticals by 220.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 9,820 shares of the company's stock valued at $66,000 after buying an additional 6,758 shares in the last quarter. Finally, Colonial River Investments LLC acquired a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at about $68,000. Hedge funds and other institutional investors own 89.06% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently commented on RXRX shares. Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Needham & Company LLC reduced their price target on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Leerink Partners cut their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research note on Friday, February 28th. Finally, Morgan Stanley reduced their target price on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of "Hold" and a consensus price target of $7.60.

Recursion Pharmaceuticals Stock Performance

Shares of Recursion Pharmaceuticals stock traded up $0.02 on Wednesday, reaching $4.41. 19,358,209 shares of the company were exchanged, compared to its average volume of 13,499,236. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The company's 50-day moving average is $5.04 and its two-hundred day moving average is $6.47. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of -2.87 and a beta of 0.99. Recursion Pharmaceuticals, Inc. has a 1-year low of $3.79 and a 1-year high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $14.75 million during the quarter, compared to analyst estimates of $18.12 million. During the same quarter in the prior year, the business earned ($0.39) earnings per share. The firm's revenue was up 7.2% compared to the same quarter last year. As a group, research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.